Regimen Reference Order – LYMP – siltuximab

ARIA: LYMP – [siltuximab]

Planned Course: **Every 21 days until disease progression or unacceptable toxicity**
Indication for Use: **HIV negative and HHV8 negative Multicentric Castleman's Disease**

CVAD: At Provider's Discretion

Proceed with treatment if:

Cycle 1

- ***ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 75 x 10^9/L***
- ***Hemoglobin less than 170 g/L***

Cycle 2 and onwards

- ***ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L***
- ***Hemoglobin less than 170 g/L***
  - ❖ **Contact Hematologist if parameters not met**

***Note:* Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LYMP - siltuximab

Establish primary solution: 250 mL D5W

Drug	Dose	CCMB Administration Guideline
cetirizine	10 mg	Orally 30 minutes prior to siltuximab
acetaminophen	650 mg	Orally 30 minutes prior to siltuximab
siltuximab	11 mg/kg	IV in D5W 250 mL over 1 hour For administration, total volume of final product should equal 250 mL. Therefore, appropriate volume of D5W should be withdrawn from 250 mL bag prior to addition of siltuximab for final volume to equal 250 mL *Use 0.22 micron filter*

All doses will be automatically rounded that fall within CCMB Approved Dose Bands. See Dose Banding document for more information

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

All Cycles

- Full vital signs (temperature, heart rate, respiration, blood pressure and O_2 saturation) at baseline
- Observe patient for 30 minutes for cycle 1. If there are no previous infusion-related reactions, then no observation period is required on subsequent cycles
- If any infusion-related reaction at any time on any infusion, then a 2-hour observation period is required

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

DISCHARGE INSTRUCTIONS

- Not applicable

ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy ***Hepatitis B Monitoring for Oncology and Hematology Patients*** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- siltuximab therapy should be withheld if the patient has a severe infection or any severe non-hematologic toxicity and can be restarted at the same dose after recovery
- If the patient develops a severe infusion-related reaction, anaphylaxis, severe allergic reaction or cytokine release syndrome related to siltuximab infusion, further administration of siltuximab should be discontinued
- siltuximab can only be administered at a site where pharmacy is on site to prepare siltuximab due to short stability
- It can take up to 90 minutes for pharmacy to prepare a siltuximab dose and siltuximab administration must be completed within 6 hours of reconstitution of the vials during the preparation process
- Cycle 1 must be given at CancerCare Manitoba MacCharles unit